What can I do when logged in?

You can submit new articles, so we can make unique versions of them and distribute them for you.
If you want to simply publish the same article on 800 websites, you can tell us to do that.
You can see the archive and current status of all your article distributions.
You can order any number of high-quality articles - just let us know your keywords.
You can browse the archive of all the articles we have written for you.
You can order our Complete Service (10 high-quality articles plus 10 article distributions).
You can purchase more credits for our services and check your affiliate earnings.
Much more ...

SpinDistribute.com Article Directory

The following article was published in our article directory on August 17, 2012.
Learn more about SpinDistribute Article Distribution System.

Diabetic Macular Edema Drug Wins FDA Approval

Article Category: Medical Business

Author Name: Kyle Lawson

The US Food and Medication Administration (FDA) has actually authorized Genentech's drug Lucentis (ranibizumab injection) for the therapy of diabetic macular edema (DME), an eye condition that can easily cause blindness in people with diabetes.

In revealing the decision to the press on Friday, the FDA said the drug is for usage with "good diabetic sugar control" and is made to be offered when a month as a shot into the eye by a certified health care professional.

Lucentis is currently approved in the US for the treatment of wet (neovascular) age-related macular degeneration (AMD), and also macular edema following retinal vein occlusion (RVO).

The macula is the location in the center of the retina, which is responsible for sharp centrol vision. Damages to this part of the eye indicates individuals lose central vision (for example they can't see faces), but not peripheral vision.

DME is swelling of the macula, and begins with diabetes, which can easily cause damage to blood vessels in the eye. The subsequent result on the retina is called diabetic retinopathy, the most common diabetic eye illness. The broken blood vessels can leak blood and fluid, which creates swelling and beclouded vision and can eventually result in severe loss of vision and blindness.

The FDA assessed 2 clinical studies, RIDE and SURGE, that tested the protection and usefulness of Lucentis as a therapy for DME.

Together, the researches treated and followed 759 clients for 3 years. The customers were arbitrarily designated to three groups: one obtained a 0.3 mg dosage (250 clients), another got a 0.5 mg dose (252), and the controls (257) received a sham drug for the very first 24 months.

At month 24, the customers underwent an eye examination where they had to check out letters arranged line by line on a vision test chart.

The outcomes showed that customers who received 0.3 mg Lucentis experienced substantial vision enhancements compared with controls but this was not the case with the higher dose.

Especially, the improvements were:
Even more clients who got the medication at 0.3 mg a dosage had the ability to review three extra lines (15 letters) on the eye chart than controls: in the RIDE study 34 % of the medicine group versus 12 % in the control group, and in the SURGE study, this was 45 % versus 18 % respectively.

Customers who got the drug at the 0.3 mg dose showed an ordinary vision improvement of more than two lines (10 letters): RIDE 10.9 versus 2.3 letters (medicine group versus controls) and SURGE 12.5 versus 2.6 letters respectively.

Signficant gain in typical vision was seen 7 days after the first treatment.

Customers who got the 0.3 mg dosage of the medication were significantly more likely to keep their vision (determined as losing far fewer than 15 letters on the eye chart): in the RIDE study, 98 % of the medicine group compared with 92 % of controls, and in the RISE research, it was 98 versus 90 % respectively.

Vision enhancements determined at 24 months in the medicine group were kept with ongoing treatment through to 36 months.
The most typical reported side effects in patients treated with the medicine consisted of bleeding of the conjunctiva (the tissue that lines the inside of the eyelids and covers the area of the white part of the eye), increased intraocular pressure (pressure inside the eye), eye discomfort and floaters.

David M Brown, Retinal Expert at The Methodist Healthcare facility, Houston Texas, and clinical trial investigator, informed the press:

"This approval is an important development in the fight against blindness for individuals with diabetic issues."

"Now that it will certainly be available, Lucentis treatment can begin to make a difference in the lives of our customers with DME," he incorporated.

Figures from the US Centers for Illness Control and Avoidance (CDC) show 26 million Americans have diabetes type 1 or type 2. The disease is the primary source of brand-new blindness among 20 to 74 year olds.

According to the 2005-2008 National Health and Nourishment Examination Study (NHANES), amongst Americans aged 40 and over, more than 4.2 million have diabetic retinopathy, and a succeeding analysis shows that over half a million have DME.

Renata Albrecht, director of the Branch of Transplant and Ophthalmology Products in the Center for Medication Assessment and Research at the FDA told the press:

"Diabetic issues is a major public health issue in our nation, and all customers with diabetes are at danger of developing diabetic macular edema."

Keywords: Health, Health tips, Healthy Life, Medical tips, medical advice

Learn more about SpinDistribute Article Distribution System. We also offer a Pro Article Writing Service to everyone who needs premium quality well-researched articles.

SpinDistribute.com Network

Each article you submit at SpinDistribute.com is sent through our innovative Article Distribution System to our network of more than 1840 publishers - about 55% of them are high-quality article directories, 30% of them are niche blogs and 15% of them are other content-rich websites.

To achieve the best possible success we only publish your article to most related websites. This means your article will show up on approximately 640 - 880 most related websites which will give you great SEO results.

We also offer a separate Professional Article Writing Service to everyone who's looking for high quality web content and well researched unique articles.